Loading clinical trials...

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions | Clinical Trials | Clareo Health

TERMINATEDPHASE4

HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions

HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

NCT03051516•Fred Hutchinson Cancer Center

View on ClinicalTrials.gov

Summary

This phase IV trial studies how well human papillomavirus (HPV) vaccine therapy works in interrupting progression in patients with high-grade vulvar or anal lesions. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill tumor cells and decrease the chance of vulvar or anal lesions to progress or come back.

Detailed Description

OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive recombinant human papillomavirus nonavalent vaccine intramuscularly (IM) at baseline, 2 months, and 6 months. ARM II: Patients receive placebo IM at baseline, 2 months, and 6 months. After completion of study treatment, patients are followed up at months 7, 12, 18, 24, 36, and 42.

Eligibility

Age

27 - 69 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Histologically confirmed diagnosis of initial or recurrent anal or vulvar high-grade squamous intraepithelial lesion (AIN2/3 or VIN2/3) diagnosed on or after 1/1/2014; study pathologist will use p16 staining as needed to rule out low-grade squamous intraepithelial lesion (LSIL) disease
•\>= 2 months since last therapy for HSIL
•No clinical evidence of HSIL on screening examination; if HSIL is suspected, a biopsy will be done to exclude HSIL; patients whose screening visit reveals HSIL on biopsy, may be re-screened \>= 2 months after therapy
•Resident in the catchment area of the clinics and willing to attend up to 8 clinic visits for a 36-month period
•Sexually active women of child-bearing potential must be willing to use effective contraception through month 7 of the study
•If human immunodeficiency virus (HIV) positive, receipt of anti-retroviral therapy continuously for at least 6 months prior to enrollment
•Ability to give informed consent
•Willingness to sign medical records release form and tissue release form

Exclusion Criteria

•Currently pregnant
•Chemotherapy (current, within the last month, or anticipated in the next 7 months)
•Prior history of invasive HPV-related anogenital cancer (cervical, vaginal, vulvar, penile, or anal cancer), or oropharyngeal cancer (base of tongue, tonsil); prior cancer at other sites (including most of oral cavity) or larynx are not exclusions
•Unstable medical condition (e.g., another malignancy requiring treatment, malignant hypertension, poorly controlled diabetes, another cancer except for fully excised non-melanoma skin cancer)
•Prior HPV vaccination
•Known allergy or intolerance to lidocaine
•Currently participating in an interventional research study related to HPV, except the Anal Cancer HSIL Outcomes Research (ANCHOR) study (NCT02135419)
•Any other condition which, in the opinion of the investigator, may compromise the subject's ability to follow study procedures and safely complete the study

Locations (2)

University of Alabama at Birmingham Cancer Center

Birmingham, Alabama, United States

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, United States

Key Dates

Start Date

August 1, 2017

Primary Completion Date

December 31, 2022

Completion Date

December 31, 2022

Last Updated

February 28, 2024

Enrollment

188

ACTUAL participants

Conditions

High Grade Anal Canal Intraepithelial NeoplasiaHigh Grade Vulvar Squamous Intraepithelial Lesion

Interventions

Laboratory Biomarker Analysis

OTHER

Placebo Administration

OTHER

Questionnaire Administration

OTHER

Recombinant Human Papillomavirus Nonavalent Vaccine

BIOLOGICAL